What Does 30× Coverage Mean in Genome Sequencing?

When you shop for whole genome sequencing, one number appears everywhere: 30×. Dante Labs offers "30× WGS." Sequencing.com advertises "30× coverage." Clinical guidelines reference "30× depth." But what does it actually mean, and why is 30 the magic number?

Coverage Depth, Explained Simply

Your genome is a long string of roughly 3.2 billion base pairs (6.4 billion if you count both copies of each chromosome). A sequencer doesn't read this string from start to finish like a book. Instead, it shatters your DNA into millions of short fragments — typically 100 to 150 base pairs long — and reads each fragment independently.

Coverage depth is the average number of times each position in your genome is read across all those fragments. At 30× coverage, every base pair in your genome is covered by an average of 30 different sequencing reads. Some positions will be covered by 20 reads, others by 40 — the "30×" is the genome-wide average.

Why Not Just Read It Once?

Sequencing technology is not perfect. Every individual read has a small probability of error at each base position — typically around 0.1–1% per base, depending on the sequencing platform and chemistry. A single read of your genome would contain millions of errors, making it clinically useless.

Redundancy solves this. When 30 independent reads cover the same position and 29 of them say "A" while one says "T," the consensus call is "A" with high confidence, and the single "T" is identified as a sequencing error. The more reads covering each position, the more accurately you can distinguish true variants (real differences in your DNA) from sequencing noise.

At 30× average coverage, the probability of a correct base call exceeds 99.9% for most positions. This is the threshold that clinical laboratories, professional guidelines (ACMG), and regulatory frameworks have established as sufficient for medical-grade variant detection.

Understanding Q30 Scores

Coverage depth (30×) tells you how many times each position was read. Q30 tells you how accurate each individual read was. They're complementary metrics — both matter.

A Q30 score means the base call has a 1 in 1,000 probability of being wrong — or, equivalently, 99.9% accuracy per base. When a provider says they achieve ">90% Q30," it means at least 90% of all bases in your sequencing run were called with 99.9% accuracy or better.

The math compounds favorably: when you combine high per-read accuracy (Q30) with high redundancy (30×), the probability of a consensus error at any given position becomes vanishingly small — typically less than 1 in 10 million for well-covered regions.

What About Higher Coverage?

If 30× is good, why not 60× or 100×? The answer is diminishing returns.

Going from 1× to 10× coverage dramatically improves accuracy. Going from 10× to 30× provides meaningful additional sensitivity, particularly for detecting heterozygous variants (positions where your two chromosome copies differ). Going from 30× to 60× provides marginal improvement for most applications — the consensus calls at 30× are already highly accurate.

The exception is cancer genomics, where somatic mutations may be present in only a fraction of cells. Tumor sequencing often uses 60×, 100×, or even higher coverage to detect low-frequency variants. But for germline sequencing — reading the DNA you were born with, which is the same in every cell — 30× is the established clinical standard.

Higher coverage also means proportionally larger files and higher costs. A 60× WGS produces roughly twice the data of a 30× run, with twice the storage requirements and processing time. For consumer genomics, the cost-benefit sweet spot is firmly at 30×.

What About Low-Pass Sequencing?

Some providers offer "low-pass" or "shallow" WGS at 0.4×–4× coverage at a lower price point. This is a fundamentally different product. At 0.4× coverage, the vast majority of positions in your genome are covered by zero or one read — meaning the data is sparse, error-prone, and requires statistical imputation to fill in the gaps.

Low-pass sequencing combined with imputation can be useful for population-level studies and ancestry analysis, but it cannot reliably detect rare variants, structural changes, or pharmacogenomic markers with clinical confidence. It is not equivalent to 30× WGS and should not be confused with it.

If a provider offers "whole genome sequencing" at a suspiciously low price without specifying 30× coverage, check the fine print. You may be getting low-pass sequencing marketed under a misleading name.

How to Verify Your Coverage

After receiving your results, you can verify the actual coverage depth achieved in your sequencing run. Most providers report this in a quality summary, but you can also calculate it from your BAM file using SAMtools:

The key metric is mean coverage across the genome. You want to see a number at or above 30. Some positions will inevitably have lower coverage due to repetitive regions or GC-content biases, but the genome-wide average should meet the 30× threshold.

If your provider reports a Q30 score, look for ≥90%. Anything significantly below this suggests lower-quality sequencing chemistry or data processing issues.

The Bottom Line

30× coverage is not a marketing number — it's a well-validated technical threshold backed by decades of research and clinical practice. It represents the point at which sequencing accuracy is sufficient for reliable variant detection across the entire human genome, including heterozygous variants, rare mutations, and pharmacogenomic markers.

When comparing WGS providers, confirm that they explicitly offer 30× coverage (not low-pass), report Q30 scores ≥90%, and use current-generation sequencing platforms (Illumina NovaSeq X series represents the current state of the art). Any reputable provider will be transparent about all three metrics.